神経障害性疼痛の世界市場

神経障害性疼痛の世界市場は2030年までに107億米ドルに達する見込み

2024年に83億米ドルと推定される神経障害性疼痛の世界市場は、2024年から2030年にかけてCAGR 4.3%で成長し、2030年には107億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗うつ剤は、CAGR 5.4%を記録し、分析期間終了時には39億米ドルに達すると予測されます。抗けいれん薬セグメントの成長率は、分析期間中CAGR 2.9％と推定されます。

米国市場は23億米ドルと推定、中国はCAGR 8.1％で成長予測

米国の神経障害性疼痛市場は、2024年に23億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.1%として、2030年までに22億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.4%と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界の神経障害性疼痛市場- 主要動向と促進要因のまとめ

神経障害性疼痛の認識と治療が慢性疼痛管理で重要な勢いを増す理由とは？

神経障害性疼痛は、神経損傷や機能障害によって引き起こされる複雑でしばしば衰弱させる慢性疼痛であり、生活の質、メンタルヘルス、ヘルスケア利用などに多大な影響を及ぼす重大な臨床的問題として浮上しています。組織の損傷や炎症に起因する侵害受容性疼痛とは異なり、神経障害性疼痛は末梢神経系または中枢神経系の病変に起因し、しばしば灼熱感、疼き、電気ショックのような感覚、または知覚過敏を特徴とします。一般的な原因としては、糖尿病性神経障害、帯状疱疹後神経痛、化学療法による神経障害、多発性硬化症、脊髄損傷、三叉神経痛などがあります。

糖尿病、がんサバイバーシップ、神経障害の有病率の増加は、神経障害性疼痛診断の世界的急増に寄与しています。しかし、神経障害性疼痛は、その自覚的な性質と従来の鎮痛薬に対する抵抗性から、診断が不十分で治療も十分でないことが多いです。臨床ガイドラインでは、早期発見と、薬理学的、介入的、心理学的手法を含む多角的治療がますます強調されています。臨床医と患者双方の意識が高まるにつれ、効果的で忍容性の高い薬物療法への需要が加速しており、神経障害性疼痛治療市場の成長を後押ししています。

薬理学的進歩と個別化治療戦略は、神経障害性疼痛の治療成績をどのように改善しているか？

神経障害性疼痛に対する現在の薬理学的治療には、第一選択薬としてガバペンチノイド（ガバペンチン、プレガバリン）、セロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）、三環系抗うつ薬（TCA）、局所リドカインまたはカプサイシン、最終手段としてオピオイドなどがあります。これらの治療法は、神経シグナル伝達の調節、神経伝達物質の放出の抑制、疼痛受容体の脱感作を目的としています。しかし、有効性にばらつきがあること、忍容性に問題があること、依存性のリスクがあることから、代替療法や補助療法への関心が高まっています。

最近の技術革新としては、ナトリウムチャネル遮断薬（ラコサミドなど）、カルシウムチャネル調節薬、カンナビノイドベースの治療薬、疼痛特異的受容体を標的とした遺伝子治療などがあります。経頭蓋磁気刺激（TMS）や経皮的電気神経刺激（TENS）などの非侵襲的神経調節技術は、マルチモーダル疼痛管理プロトコールに組み込まれつつあります。疼痛表現型、定量的感覚検査、デジタル疼痛追跡などの治療法の進歩により、よりオーダーメイドでダイナミックな治療戦略が可能になりつつあります。これらの開発により、慢性的な神経障害性疼痛へのアプローチ方法が再定義されつつあり、試行錯誤的な処方から、エビデンスに基づいた患者固有のケアパスへと移行しつつあります。

神経障害性疼痛市場を牽引する患者集団と地域ヘルスケアシステムとは？

神経障害性疼痛市場を牽引している主な患者グループには、糖尿病患者（特に痛みを伴う糖尿病性末梢神経障害の患者）、化学療法を受けているがんサバイバー、脳卒中後や手術後の神経損傷を持つ高齢患者、脊髄障害や多発性硬化症の患者が含まれます。男女差も認められ、女性の方が痛みの強さや治療抵抗性が高いと報告されています。慢性疼痛の有病率は高齢化社会で顕著に高く、人口動態が不均衡な地域での需要がさらに高まっています。

北米は、高いヘルスケア支出、慢性疾患の蔓延、疼痛管理専門医へのアクセスの良さから市場をリードしています。欧州は、強力な臨床ガイドラインと非オピオイド鎮痛ソリューションへの注目が高まっており、これに続いています。アジア太平洋は、急速な都市化、糖尿病罹患率の上昇、インド、中国、日本などの国々における専門医療へのアクセスの拡大により、著しい成長を遂げています。ラテンアメリカとアフリカの一部では、依然として未診断の市場が残っていますが、遠隔医療、モバイルヘルスアプリ、慢性疼痛リテラシーをターゲットとした社会啓発キャンペーンを通じて成長が見込まれています。

神経障害性疼痛市場の長期的イノベーションと商業的拡大の原動力は？

神経障害性疼痛市場の成長は、疾病発生率の増加、診断能力の向上、根本的な神経機能障害に対処する標的療法の革新によって促進されます。オピオイド・スチュワードシップが世界の優先課題となる中、安全性と有効性に優れた代替鎮痛薬への投資が進んでいます。研究開発パイプラインは、生物学的製剤、イオンチャンネルモジュレーター、RNAベースの治療薬、神経炎症や疼痛感作経路を標的とするモノクローナル抗体などへと拡大しています。

規制機関は、特に希少または治療抵抗性の疼痛症候群におけるアンメットニーズに対応する治療薬について、迅速化された経路を通じて新規製品の承認を支援しています。コンパニオン診断薬とデジタルヘルスの統合は、ダイナミックな用量漸増とより良いアドヒアランスモニタリングを可能にしています。慢性疼痛管理が学際的な取り組みとなるにつれ、単なる症状抑制にとどまらない精密医療、統合ケア、患者中心のアウトカムへのシフトを背景に、神経障害性疼痛市場は持続的な成長を遂げる態勢が整っています。

セグメント

薬剤クラス（抗うつ薬、抗けいれん薬、オピオイド、カプサイシン、その他薬剤クラス別）、適応症（糖尿病性神経障害、脊柱管狭窄症、化学療法誘発性末梢神経障害、その他適応症）、流通チャネル（病院薬局、ドラッグストア・小売薬局、オンライン薬局）

調査対象企業の例（注目の44社）

• AbbVie Inc.
• Akelos Inc.
• Averitas Pharma, Inc.
• BioLineRx Ltd.
• Bristol-Myers Squibb Company
• Dogwood Therapeutics
• Eli Lilly and Company
• GlaxoSmithKline plc（GSK）
• Grunenthal GmbH
• Johnson & Johnson
• Lexicon Pharmaceuticals, Inc.
• Mallinckrodt Pharmaceuticals
• Neuropathix Inc.
• Pfizer Inc.
• Sanofi S.A.
• SiteOne Therapeutics
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Trevena, Inc.
• Vertex Pharmaceuticals Incorporated

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Neuropathic Pain Market to Reach US$10.7 Billion by 2030

The global market for Neuropathic Pain estimated at US$8.3 Billion in the year 2024, is expected to reach US$10.7 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Anticonvulsant segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.1% CAGR

The Neuropathic Pain market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Neuropathic Pain Market - Key Trends & Drivers Summarized

Why Is Neuropathic Pain Recognition and Treatment Gaining Critical Momentum in Chronic Pain Management?

Neuropathic pain, a complex and often debilitating form of chronic pain caused by nerve damage or dysfunction, has emerged as a significant clinical concern with far-reaching implications for quality of life, mental health, and healthcare utilization. Unlike nociceptive pain, which results from tissue injury or inflammation, neuropathic pain arises from lesions in the peripheral or central nervous system and is often characterized by burning, tingling, electric shock-like sensations, or hypersensitivity. Common causes include diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced neuropathy, multiple sclerosis, spinal cord injuries, and trigeminal neuralgia.

The rising prevalence of diabetes, cancer survivorship, and neurological disorders is contributing to a global surge in neuropathic pain diagnoses. However, due to its subjective nature and resistance to conventional analgesics, neuropathic pain is frequently underdiagnosed and undertreated. Clinical guidelines increasingly emphasize early identification and multidimensional therapy involving pharmacological, interventional, and psychological modalities. As awareness grows among both clinicians and patients, the demand for effective and well-tolerated pharmacotherapies is accelerating, propelling the growth of the neuropathic pain treatment market.

How Are Pharmacological Advances and Personalized Treatment Strategies Improving Outcomes in Neuropathic Pain?

Current pharmacological treatments for neuropathic pain include first-line agents such as gabapentinoids (gabapentin, pregabalin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), topical lidocaine or capsaicin, and opioids as a last resort. These therapies aim to modulate neural signaling, inhibit neurotransmitter release, or desensitize pain receptors. However, variable efficacy, tolerability issues, and the risk of dependence have spurred interest in alternative and adjunctive therapies.

Recent innovations include sodium channel blockers (e.g., lacosamide), calcium channel modulators, cannabinoid-based therapies, and gene therapy targeting pain-specific receptors. Non-invasive neuromodulation techniques-such as transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS)-are being incorporated into multimodal pain management protocols. Advances in pain phenotyping, quantitative sensory testing, and digital pain tracking are enabling more tailored and dynamic treatment strategies. These developments are redefining how chronic neuropathic pain is approached-shifting from trial-and-error prescribing to evidence-informed, patient-specific care pathways.

Which Patient Cohorts and Regional Healthcare Systems Are Driving the Neuropathic Pain Market?

Key patient groups driving the neuropathic pain market include individuals with diabetes (especially those with painful diabetic peripheral neuropathy), cancer survivors undergoing chemotherapy, elderly patients with post-stroke or post-surgical nerve damage, and individuals with spinal disorders or multiple sclerosis. Gender disparities are also observed, with women reporting higher pain intensity and treatment resistance. Chronic pain prevalence is notably higher in aging populations, further intensifying demand in regions with demographic imbalances.

North America leads the market due to high healthcare spending, widespread chronic disease burden, and robust access to pain management specialists. Europe follows with strong clinical guidelines and a growing focus on non-opioid pain control solutions. Asia-Pacific is experiencing significant growth due to rapid urbanization, rising diabetes prevalence, and expanding access to specialty care in countries like India, China, and Japan. Latin America and parts of Africa remain underdiagnosed markets but are expected to grow through telemedicine, mobile health apps, and public awareness campaigns targeting chronic pain literacy.

What Is Powering Long-Term Innovation and Commercial Expansion in the Neuropathic Pain Market?

The growth in the neuropathic pain market is fueled by increasing disease incidence, improved diagnostic capabilities, and innovation in targeted therapies that address underlying neurological dysfunction. As opioid stewardship becomes a global priority, investment is flowing into alternative analgesics with better safety and efficacy profiles. R&D pipelines are expanding to include biologics, ion channel modulators, RNA-based therapeutics, and monoclonal antibodies that target neural inflammation and pain sensitization pathways.

Regulatory bodies are supporting novel product approvals through expedited pathways, especially for therapies addressing unmet needs in rare or treatment-refractory pain syndromes. Companion diagnostics and digital health integrations are enabling dynamic dose titration and better adherence monitoring. As chronic pain management becomes a multidisciplinary endeavor, the neuropathic pain market is poised for sustained growth-anchored by a shift toward precision medicine, integrated care, and patient-centric outcomes that extend beyond mere symptom suppression.

SCOPE OF STUDY:

The report analyzes the Neuropathic Pain market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antidepressants, Anticonvulsant, Opioids, Capsaicin, Other Drug Classes); Indication (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications); Distribution Channel (Hospital Pharmacies, Drugs Stores & Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Akelos Inc.
• Averitas Pharma, Inc.
• BioLineRx Ltd.
• Bristol-Myers Squibb Company
• Dogwood Therapeutics
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• Grunenthal GmbH
• Johnson & Johnson
• Lexicon Pharmaceuticals, Inc.
• Mallinckrodt Pharmaceuticals
• Neuropathix Inc.
• Pfizer Inc.
• Sanofi S.A.
• SiteOne Therapeutics
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Trevena, Inc.
• Vertex Pharmaceuticals Incorporated

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Neuropathic Pain - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Diabetes and Chemotherapy-Induced Neuropathy Propels Demand for Neuropathic Pain Therapies
  • Emergence of Novel Ion Channel Modulators Expands Treatment Portfolio and Market Penetration
  • Regulatory Approvals of Dual-Mechanism Analgesics Strengthen Business Case for Neuropathic Pain Drugs
  • Advancements in Peripheral Nerve Stimulation Techniques Drive Adoption of Device-Based Therapies
  • Increased Recognition of Central Sensitization Pathways Spurs Innovation in Drug Targets
  • Availability of Extended-Release Formulations Enhances Patient Adherence and Therapy Outcomes
  • Growing Integration of Neuropathic Pain Assessment Tools Strengthens Personalized Treatment Approaches
  • Rising Geriatric Population Sustains Growth in Age-Associated Neuropathic Pain Management
  • Expansion of Off-Label Prescriptions Creates Market Opportunities for Existing CNS Drugs
  • Integration of Digital Pain Tracking Platforms Throws the Spotlight on Telehealth-Based Monitoring
  • Surge in Research Funding for Pain Pathophysiology Accelerates Drug Discovery Pipelines
  • Adoption of Combination Pharmacotherapy Enhances Efficacy in Treatment-Resistant Cases
  • Stringent Opioid Regulation Frameworks Drive Shift Toward Non-Opioid Neuropathic Pain Solutions
  • Clinical Emphasis on Early Diagnosis Supports Preventive Pharmacological Interventions
  • Rising Demand for Non-Addictive Analgesics Spurs Interest in Novel Drug Mechanisms
  • Availability of Neuropathic Pain Biomarkers Strengthens Role of Predictive Diagnostics
  • Challenges in Regulatory Approval Timelines Pose Delays for First-in-Class Therapies
  • Growing Use of CBD-Derived Formulations Expands Alternative Pain Management Landscape
  • Integration of Artificial Intelligence in Drug Repurposing Enhances Pipeline Diversification
  • Increased Patient Awareness Through Advocacy Campaigns Generates Therapy Demand
  • Regional Variability in Pain Management Guidelines Creates Fragmentation in Market Penetration
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neuropathic Pain Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Anticonvulsant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Anticonvulsant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Anticonvulsant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Capsaicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Capsaicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Capsaicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Drugs Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Drugs Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Drugs Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diabetic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diabetic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Diabetic Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Spinal Stenosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Spinal Stenosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Spinal Stenosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• CHINA
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Neuropathic Pain by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Neuropathic Pain by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• INDIA
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Neuropathic Pain by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Neuropathic Pain by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION